Archana Asundi, MD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Archana Asundi is a physician-scientist and infectious disease clinician, who specializes in care of people living with HIV with a specific focus on HIV and Aging. In her role Director of the Infectious Disease Clinical Research Unit (ID-CRU) at Boston Medical Center, she supports and oversees the conduct of a large portfolio of clinical trials and clinical-translational research studies in the Center for Infectious Disease (CID). Her individual research program focuses on investigating cardiometabolic comorbidities and weight gain/obesity among people living with HIV. She also engages in quality improvement and continuing medical education in the area of HIV and aging with several projects ongoing targeted around improvement of health-related quality of life among people aging with HIV.

Publications

  • Published 5/19/2025

    Bean DJ, Liang YM, Avila F, He X, Asundi A, Sagar M. Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies. J Virol. 2025 May 19; e0055025. PMID: 40387363.

    Read at: PubMed

  • Published 2/1/2025

    Pickering RT, Asundi A, Olson A, Soden K, Kuritzkes DR, Lin NH. Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir. Antivir Ther. 2025 Feb; 30(1):13596535251314571. PMID: 39953931.

    Read at: PubMed

  • Published 11/22/2024

    Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. HIV-1 latency reversal agent boosting is not limited by opioid use. JCI Insight. 2024 Nov 22; 9(22). PMID: 39470739.

    Read at: PubMed

  • Published 5/15/2024

    Pihl RMF, Smith-Mahoney EL, Olson A, Yuen RR, Asundi A, Lin N, Belkina AC, Snyder-Cappione JE. Vd1 Effector and Vd2 ?d T-Cell Subsets Shift in Frequency and Are Linked to Plasma Inflammatory Markers During Antiretroviral Therapy-Suppressed HIV Infection. J Infect Dis. 2024 May 15; 229(5):1317-1327. PMID: 38390982.

    Read at: PubMed

  • Published 6/3/2023

    Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting. medRxiv. 2023 Jun 03. PMID: 37398278.

    Read at: PubMed

View All 17 Publications:   View Full Profile in BUMC

Websites

Education

  • McGill University, MD
  • Tufts University, BA

View all profiles